论文部分内容阅读
目的:对辛伐他汀与贝那普利单用或联用治疗糖尿病肾病的临床疗效进行观察和分析。方法:选择75例于2012年1月至2013年7月间在我院进行糖尿病肾病治疗的患者资料进行研究和分析,将患者分为对照组、治疗组和观察组三组,每组各有25例患者,对对照组患者进行贝那普利治疗,对治疗组患者进行辛伐他汀治疗,对观察组患者进行贝那普利联合辛伐他汀治疗,比较和分析三组患者的治疗效果。结果:治疗组患者在升高HDL-C,降低TG、LDL-C以及TC方面的效果明显优于对照组患者,观察组患者在上述方面的治疗效果明显优于对照组和观察组。治疗组患者的血压下降幅度明显低于观察组与对照组。对照组患者的SBP下降幅度明显低于观察组患者。三组患者治疗后血糖、Scr、Ccr变化差异不显著,对照组以及治疗组患者UAER下降幅度明显低于观察组,观察组Alb增长幅度以及尿蛋白下降幅度均明显高于对照组和治疗组。结论:对治疗糖尿病肾病患者进行辛伐他汀联合贝那普利治疗能够取得更加理想的治疗效果,能够使患者肾脏获得有效保护,值得推广和应用。
Objective: To observe and analyze the clinical efficacy of simvastatin and benazepril alone or in combination with diabetic nephropathy. Methods: The data of 75 patients with diabetic nephropathy treated in our hospital from January 2012 to July 2013 were selected and analyzed. The patients were divided into three groups: control group, treatment group and observation group. Each group had In the 25 patients, the patients in the control group were treated with benazepril, the patients in the treatment group were treated with simvastatin, the patients in the observation group were treated with benazepril combined with simvastatin, and the therapeutic effects were compared and analyzed among the three groups. Results: The treatment group was significantly better than the control group in increasing HDL-C, lowering TG, LDL-C and TC, and the treatment group in the treatment group was significantly better than the control group and the observation group in the above aspects. The treatment group patients with blood pressure decreased significantly lower than the observation group and the control group. The SBP decrease in the control group was significantly lower than that in the observation group. The changes of blood glucose, Scr and Ccr were not significantly different between the three groups after treatment. The decrease of UAER in the control group and the treatment group was significantly lower than that in the observation group. Alb growth rate and urinary protein decrease in the observation group were significantly higher than those in the control group and the treatment group. Conclusion: Simvastatin combined with benazepril in patients with diabetic nephropathy can achieve more ideal therapeutic effect, which can effectively protect the kidney of patients and is worthy of popularization and application.